2016 AGM MD and CEO Presentation
Filed with ASX · · 27 pages · English
This presentation was prepared by Genetic Signatures Limited known as “Genetic Signatures“, (“GSS” or “the Company”), in order to discuss its business with various interested parties. This presentation in its entirety has been released to the market via the Australian Securities Exchange Limited (“ASX”). This presentation contains statements that involve estimates, risks and uncertainties. Althoug
Genetic Signatures Ltd. on 6ix
In the deck
Earlier from Genetic Signatures
- STI Detection Kit Clinical Validation Trial Results
- Open Briefing - Capital Raising and Company Outlook
- Clinical Validation of Sexual Health Detection Kit Commenced
- Completion of $14m capital raising
- UCLA to launch Genetic Signatures technology
Later from Genetic Signatures
- Appendix 4D - Half Yearly Report and Accounts
- GSS Launches Sexually Transmitted Infection (STI) Kit
- Results of Flavivirus Clinical Trial
- Regulatory and Patent approval
- Appendix 4E and 2017 Financial Report
Follow Genetic Signatures into a list and get an email when it puts out news.
Follow Genetic Signatures